# Ivabradine

## Coralan 5mg

| 藥物代碼 | OCOR5 |
| :--- | :--- |
| 適應症 | Heart failure: Reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction ?35%, who are in sinus rhythm with resting heart rate ?70 beats per minute \(bpm\) and either are on maximally tolerated doses of beta blockers or have a contraindication to beta-blocker use. |
| 副作用 | Cardiovascular: Bradycardia \(6% to 10%\), hypertension \(9%\), atrial fibrillation \(5% to 8%\), heart block, sinoatrial arrestCentral nervous system: Phosphene \(3%\)&lt;1% \(Limited to important or life-threatening\): Angioedema, diplopia, erythema, hypotension, pruritus, skin rash, syncope, urticaria, vertigo, visual impairment. |
| 禁忌 | Acute decompensated heart failure; blood pressure &lt;90/50 mm Hg; sick sinus syndrome, sinoatrial block, or third-degree AV block \(unless a functioning demand pacemaker is present\); resting heart rate &lt;60 bpm prior to treatment; severe hepatic impairment; pacemaker dependence \(heart rate maintained exclusively by the pacemaker\); concomitant use with strong CYP3A4 inhibitors. |
| 藥物保存方式 | 室溫 |
| 用法用量 | Oral: Initial: 5 mg twice daily or 2.5 mg twice daily in patients with a history of conduction defects or who may experience hemodynamic compromise due to bradycardia. After 2 weeks, adjust dose to achieve a resting heart rate between 50 and 60 beats per minute \(bpm\). Thereafter, adjust dose as needed based on resting heart rate and tolerability. Maximum dose: 7.5 mg twice daily. |
| 肝功能異常 | 無需調整劑量  禁止使用於重度肝功能不全之病人 |
| 腎功能異常 | 無需調整劑量 |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity 無\(很少\)資料 - 避免使用 |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | N/A |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

